Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 386-397
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.386
Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial
Vilma Pacheco-Barcia, Sara Custodio-Cabello, Fatima Carrasco-Valero, Magda Palka-Kotlowska, Axel Mariño-Mendez, Alberto Carmona-Bayonas, Javier Gallego, A J Muñoz Martín, Paula Jimenez-Fonseca, Luis Cabezon-Gutierrez
Vilma Pacheco-Barcia, Sara Custodio-Cabello, Magda Palka-Kotlowska, Luis Cabezon-Gutierrez, Department of Medical Oncology, Hospital Universitario de Torrejon, Madrid 28850, Spain
Fatima Carrasco-Valero, Department of Internal Medicine, Hospital Universitario de Torrejon, Madrid 28850, Spain
Axel Mariño-Mendez, Paula Jimenez-Fonseca, Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo 33011, Spain
Alberto Carmona-Bayonas, Department of Medical Oncology, Hospital Universitario Morales Meseguer, University of Murcia, Murcia 30001, Spain
Javier Gallego, Department of Medical Oncology, Hospital General Universitario de Elche, Elche 03202, Spain
A J Muñoz Martín, Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, Madrid 28007, Spain
Luis Cabezon-Gutierrez, Universidad Francisco de Vitoria, Madrid 28223, Spain
Author contributions: Pacheco-Barcia V, Mariño-Mendez A, and Jimenez-Fonseca P contributed to the conceptualization and project administration; Pacheco-Barcia V, Mariño-Mendez A, Jimenez-Fonseca P, and Cabezon-Gutierrez L were involved in the methodology and validation; Pacheco-Barcia V participated in the software, formal analysis, and data curation; Pacheco-Barcia V, Custodio-Cabello S, Carrasco-Valero F, Palka-Kotlowska M, Mariño-Mendez A, Carmona-Bayonas A, Gallego J, Martín AJM, Jimenez-Fonseca P, and Cabezon-Gutierrez L took part in the investigation of this study; Pacheco-Barcia V and Carrasco-Valero F contributed to the resources of this article; Pacheco-Barcia V, Jimenez-Fonseca P, and Cabezon-Gutierrez L wrote original draft; Pacheco-Barcia V, Carrasco-Valero F, and Jimenez-Fonseca P contributed to the writing, review and editing of this article; Custodio-Cabello S and Palka-Kotlowska M were involved in the visualization of this manuscript; Mariño-Mendez A, Jimenez-Fonseca P, and Cabezon-Gutierrez L participated in the supervision; and all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study adhered to the ethical standards of the committee responsible for human experimentation (both institutional and national) and aligned with the 1975 Helsinki Declaration, as updated in 2008. The local ethics committee and Institutional Review Board approved the study under version 3.5, code PANT-SP-2023-01.
Informed consent statement: Consent was obtained from all patients who were alive at the time of data collection.
Conflict-of-interest statement: Pacheco-Barcia V: Advisory role: Advanced accelerator applications, a Novartis company. Speakers’ bureau: Merck, Eli Lilly, Eisai, Pierre Fabre. Congress attendance: Merck, Amgen, Merck Sharp and Dhome, Nutricia. Grant support: FSEOM and Merck. Other: Amgen. Martín AJM: Consultant or advisory role: GSK, Sanofi, Pfizer-BMS, Celgene, Leo Pharma, Incyte, Astra Zeneca, MSD, Lilly, Servier, Bayer, Roche. Research funding: Leo Pharma, Sanofi, Celgene. Speakers’ bureau: Rovi, Bayer, Menarini, Stada, Daichii Sankyo. Patents, Royalties. Other intellectual property: Risk assessment model in venous thromboembolism in cancer patients. Other authors declare no conflicts of interest related to this study.
Data sharing statement: Data supporting reported results can be requested from the authors.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vilma Pacheco-Barcia, MD, MSc, PhD, Doctor, Department of Medical Oncology, Hospital Universitario de Torrejon, C/Mateo Inurria S/N, Madrid 28850, Spain. vepacheco@torrejonsalud.com
Received: October 26, 2023
Peer-review started: October 26, 2023
First decision: December 2, 2023
Revised: December 14, 2023
Accepted: January 10, 2024
Article in press: January 10, 2024
Published online: February 15, 2024
Processing time: 98 Days and 12.5 Hours
Core Tip

Core Tip: Advancements in the therapeutic landscape for pancreatic cancer have been modest in the recent years and the prognostic potential of the Systemic Inflammation Response Index (SIRI) in advanced pancreatic cancer has garnered interest. Originating from the PANTHEIA-Spanish Society of Medical Oncology (SEOM) initiative, a multicentric, observational, study promoted by the SEOM Real World-Evidence work group, our pilot research seeks to bridge this knowledge gap. Specifically, we focused on the interplay between weight loss and the inflammatory state as demarcated by SIRI. A significant correlation between elevated SIRI levels and decreased survival in patients with metastatic pancreatic cancer, with a notable association with weight loss, was observed.